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Abstract
Background: The incidence of brain metastases in breast cancer (BCBM) patients is increasing. These patients have
a very poor prognosis, and therefore, identification of blood-based biomarkers, such as circulating tumor cells (CTCs),
and understanding the genomic heterogeneity could help to personalize treatment options.
Methods: Both EpCAM-dependent (CellSearch® System) and EpCAM-independent Ficoll-based density centrifugation
methods were used to detect CTCs from 57 BCBM patients. DNA from individual CTCs and corresponding primary
tumors and brain metastases were analyzed by next-generation sequencing (NGS) in order to evaluate copy number
aberrations and single nucleotide variations (SNVs).
Results: CTCs were detected after EpCAM-dependent enrichment in 47.7% of the patients (≥ 5 CTCs/7.5 ml blood in
20.5%). The CTC count was associated with ERBB2 status (p = 0.029) of the primary tumor as well as with the prevalence
of bone metastases (p = 0.021). EpCAM-independent enrichment revealed CTCs in 32.6% of the patients, especially
among triple-negative breast cancer (TNBC) patients (70.0%). A positive CTC status after enrichment of either method
was significantly associated with decreased overall survival time (p < 0.05). Combining the results of both enrichment
methods, 63.6% of the patients were classified as CTC positive. In three patients, the matched tumor tissue and single
CTCs were analyzed by NGS showing chromosomal aberrations with a high genomic clonality and mutations
in pathways potentially important in brain metastasis formation.
Conclusion: The detection of CTCs, regardless of the enrichment method, is of prognostic relevance in BCBM
patients and in combination with molecular analysis of CTCs can help defining patients with higher risk of
early relapse and suitability for targeted treatment.
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Background
Breast cancer represents the most frequent malignancy
among women worldwide. Due to the development of
new therapeutic options, the life expectancy of breast
cancer patients has increased steadily. Nevertheless,
breast cancer still constitutes one of the main causes of
death in young women in western countries and the over-
whelming majority of deaths are due to metastases [1, 2].
Breast cancer brain metastasis (BCBM), which occurs in
approximately 20–40% of patients with metastatic breast
cancer, is associated with high morbidity and poor prog-
nosis. The incidence appears to be increasing over the last
years, possibly as a result of better therapeutic options for
the primary tumors and extracranial metastases [3]. Even
after intensive multimodal therapy including resection
and radiotherapy, brain metastases are correlated with a
poor prognosis, consisting of a median survival time from
diagnosis between 4 and 24months [4, 5]. For this reason,
novel and improved therapeutic approaches for BCBM
patients are urgently needed. The molecular mecha-
nisms leading to BCBM formation are still incompletely
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understood. The development of new therapeutic ap-
proaches requires, however, detailed understanding of
BCBM formation and identification of key drivers of
this process. Studies investigating molecular and genetic
deviations, which are linked to BCBM, hold promise for
prevention of high-risk breast cancer patients for develop-
ing brain metastases [3]. We and others have shown that
brain metastases harbor additional new aberrations that
could not be found in the corresponding primary tumors,
highlighting the importance of investigating metastatic
cells instead of the primary tumor only [6–8].
Circulating tumor cells (CTCs) have gained much atten-
tion, as they are essential for metastasis formation having
both prognostic and predictive value in both primary and
metastatic breast cancer [9]. CTCs represent a diagnostic
source which can be obtained minimal-invasively. Having
already undergone several steps needed for successful me-
tastasis, further molecular characterization of these cells
may be used as an aid in treatment planning and help to
understand the molecular mechanism behind brain metas-
tasis formation [10].
In the current study, we assessed the presence of CTCs
in BCBM patients by two different enrichment approaches
and characterized both CTCs, primary tumors, and corre-
sponding brain metastases by next-generation sequencing
(NGS) in order to investigate the molecular alterations as-
sociated with BCBM and its genomic progression towards
metastasis.
Material and methods
Patient material
This study was performed in accordance with the Dec-
laration of Helsinki. Fifty-seven BCBM patients were
enrolled into the study after informed consent was ob-
tained (Ethics Committee of the Medical Board Hamburg
approval reference number PV3779). Two tubes of 7.5 ml
blood were collected per patient prior to clinical interven-
tion: 38/57 before surgical resection for brain metastasis
and 19/57 prior to chemo- or radiotherapy. Thirty-two
(56%) patients were diagnosed with an ERBB2-positive
primary breast tumor, ten (17.5%) with triple-negative
breast cancer (TNBC), and nine (16%) with a hormone
receptor (HR) positive tumor. From six cases, the ERBB2
status of the primary tumor was not recorded. The aver-
age time between primary diagnosis and diagnosis of brain
metastases was 49months (range 0–180months). Thirty-
seven (64.9%) of the patients showed multiple metastases,
whereas 18 (31.6%) of the patients had solitary brain me-
tastases. Median follow-up was 19months (range 0–113).
Circulating tumor cell (CTC) detection
In order to obtain CTCs from blood, two enrichment
methods were employed. The EpCAM-independent assay
was performed as described before [11]. Per patient, 7.5
ml peripheral blood was collected in an EDTA tube and
transferred on Ficoll (GE Healthcare). The mononuclear
cell fraction was obtained by centrifugation at 1400 rpm
for 20min at 4 °C with brakes off. The cells were resus-
pended in 50ml PBS and spun down on cytospins (500,
000 cells per slide). If necessary, erythrocyte-lysis (Whole
Blood Erythrocyte Lysing Kit, R&D Method Systems,
Minneapolis) was performed for 3min before. Cytospins
were dried overnight and stored at − 80 °C until use. CTCs
were detected by multicolor immunofluorescence (IF)
staining using a combination of antibodies targeting breast
cancer and epithelial cell-specific markers. For ERBB2-
and hormone receptor-positive patients, a cocktail of kera-
tin antibodies (1:80 AE1/AE3 eFluor570, eBioscience, San
Diego, California; A45 Cy3, Micromet, Munich) was used
in combination with DAPI and an ERBB2 antibody (Cell-
Search). CTCs from TNBC patients were detected using
the same keratin antibody cocktail, DAPI, and an EGFR
antibody (1:50 Biotin, Thermo Scientific, Waltham,
Massachusetts). CD45 antibody (1:150 Alexa Fluor 647,
BioLegend, San Diego) was used as an exclusion marker
for leukocytes. Slides with cells were manually analyzed
with a fluorescence-microscope (Zeiss, AxioVision, Jena).
In parallel, a second 7.5-ml blood sample from each
patient was collected in CellSave collection tubes to be an-
alyzed by the CellSearch® System as previously described
[12]. CTCs captured by EpCAM antibodies were detected
by antibodies against keratins 8, 18, and 19. DAPI was
used to stain nuclear material and antibody against CD45
for negative depletion, excluding leukocytes.
Whole genome amplification (WGA) and quality control of
CTCs
Single CTCs were picked by micromanipulation (micro
injector CellTramVario and micromanipulator Transfer-
ManNKII, Eppendorf Instruments, Hamburg, Germany)
from three different patients. The genomes of the picked
cells were amplified by whole genome amplification
(WGA) using the MDA-PCR PicoPlex WGA kit for
single cells (New England Biolabs, E2620L) as described
before [13]. A quality control of the WGA product was
performed by a multiplex PCR of the GAPDH gene
using primers to amplify products of 100, 200, 300, and
400 bp fragments [14]. The PCR products were analyzed
using a 2% agarose TAE gel, and samples producing
three or four bands were chosen for the NGS analyses.
As a positive control, human leukocyte DNA was used.
DNA extraction from tumor samples
From all three cases of whom CTCs were subjected to
WGA, the tissue of the corresponding primary tumor
was available. In one of these cases, the tissue of the cor-
responding brain metastasis was also available. DNA was
isolated from formalin-fixed, paraffin-embedded (FFPE)
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tissue blocks using macrodissection in order to achieve a
minimum of 70% tumor cells in the sample. DNA was ex-
tracted using the InnuPREP DNA Microkit according to
the manufacturer’s protocol (Analytik Jena, Jena, Germany).
Next-generation sequencing
DNA from the tumor tissues and amplified DNA from
single cells underwent whole exome sequencing using
the Illumina HiSeq2000 platform. SNV and CNA data
analyses were performed using our custom single-cell NGS
pipeline as described elsewhere [13]. Briefly, Control-
FREEC was employed to evaluate the copy number aberra-
tions with a window size of 500 kb [15]. Copy numbers 2
or 3 were considered “unchanged” in samples with diploid
and triploid genomes, respectively; fewer copy numbers
were classified as “loss” and more as “gain.” Genetic variant
annotation and functional effect prediction was performed
using SnpEff [16]. NGS data can be accessed via the
European Nucleotide Archive (https://www.ebi.ac.uk/ena)
under accession number EGAD00001005020.
ARID1A immunohistochemical analysis
Tissue microarrays (TMA) with 132 surgical tissue spec-
imens from histologically proven breast cancer brain
metastases [7] were used for immunohistochemistry
(IHC) staining of ARID1A protein. TMA slides were
de-paraffinized in xylol and rehydrated by decreasing
ethanol series followed by antigen unmasking by boiling
in citrate buffer for 5 min at 120 °C (Citra Plus, Bio-
Genex). Primary mouse monoclonal ARID1A antibody
was diluted 1:500 (sc-32761, Santa Cruz Biotechnology)
in Dako REAL Antibody Diluent (Agilent Technologies),
and the TMA slide was incubated at 4 °C overnight. For
visualization, Dako REAL Detection System was used
(K5001, Agilent Technologies). Signal intensity (grading
0–3) and signal distribution (percentage of stained cells)
were multiplied to a final value and grouped according
to the final value into negative (0–0.5), intermediate
(0.6–2), and strong (≥ 2) staining.
Statistical analyses
The CellSearch® System has been cleared by the FDA for
CTC analysis in metastatic breast cancer patients using a
cutoff of ≥ 5 CTC for positivity [17]. Due to the low
frequency of CTCs identified by the EpCAM-independent
method, a cutoff of ≥ 1 CTC was used. Statistical analyses
were performed using R version 3.5.1 (R Foundation for
Statistical Computing) and In-Silico Online, version 2.0
[18]. The G test with Williams’ correction or two-tailed
T test was employed to identify group differences and
associations between investigated variables and clinico-
histopathological risk factors. Kaplan-Meier estimates
with the log-rank test were used to analyze survival dif-
ferences between the groups. Cox proportional hazard
function was used for multivariable analyses. Unsuper-
vised complete hierarchical clustering was employed using
Euclidian distance on the chromosomal aberration status
gain, loss, and unchanged as determined by Control-
FREEC. An alpha level of 0.05 was employed to call statis-
tical significance.
Results
CTC detection in blood samples from BCBM patients
CellSearch results were obtained from 44 patients. Using
this EpCAM-dependent method, ≥ 5 CTCs/7.5 ml blood
were found in 9 patients (20.5%) and 1–4 CTCs/7.5ml
blood were found in 12 patients (27.3%) (Fig. 1); the me-
dian number of CTCs detected was 4 CTCs/7.5ml blood
(range 1–1800). In parallel, the EpCAM-independent
method based on Ficoll density gradient centrifugation was
used to isolate CTCs according to their physical properties
from blood samples of 46 patients. All cases were investi-
gated for keratins and CD45. In addition, EGFR and
ERBB2 expression were assessed in the TNBC cases and
the ERBB2-positive and hormone receptor (HR)-positive
cases, respectively. Altogether, 15 patients (32.6%) had
detectable CTCs with a median number of three CTCs per
7.5ml (range 1–40) (Table 1). In 60% of the TNBC pa-
tients, the CTCs were positive for both EGFR and keratins,
whereas in 40% the CTC were positive for keratins only.
Among the ERBB2-positive cases, a very heterogeneous
ERBB2 expression was seen: in one patient, one CTC was
detected by ERBB2 expression while being negative for ker-
atins; of two cases, all CTCs were positive for keratins but
negative for ERBB2; two patients had keratin and ERBB2-
positive CTCs only; one case had five CTCs that were posi-
tive for keratin, but only two of them were also positive for
ERBB2; finally, in two patients with an ERBB2-positive
primary tumor, the single detected keratin-positive CTCs
were found to be negative for ERBB2.
In total, 33 cases were analyzed by both the EpCAM-
dependent and EpCAM-independent methods. Based on
either one of the enrichment methods, 45.6% of the patients
had at least one detectable CTC (Fig. 1). Comparing the
two techniques revealed a fair agreement (Cohen’s kappa
0.34, p = 0.0249), 23.5% and 8.8% of the patients were solely
positive for CTCs according to the EpCAM-independent
and EpCAM-dependent method, respectively. However, no
correlation could be found between the number of CTCs
detected after EpCAM-dependent enrichment and those
after EpCAM-independent enrichment (tau = 0.0875, p =
0.6532), indicating that different CTC populations were
detected through the different enrichment techniques.
Clinical value of detected CTCs
No association could be observed between the detection
of CTCs and age or tumor histology (Table 1). In relation
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to different breast cancer histological subtypes, CTCs
detected by the EpCAM-independent method were more
common in patients with HR-negative, as well as ERBB2-
negative breast cancers as compared to patients with
HR-positive or ERBB2-positive breast cancer, respectively
(p < 0.05, G test). Thus, CTCs detected after enrichment
by the EpCAM-independent method were most com-
monly found among TNBC patients (7/41), followed by
ERBB2-positive cases (2/41) and HR-positive cases (6/41)
(p = 0.044, G test). In contrast, the EpCAM-dependent
method detected more CTCs among ERBB2-negative cases.
Furthermore, based on the results obtained by EpCAM-
dependent CTC enrichment, patients with additional bone
metastases showed more CTCs (7/44) than patients with-
out bone metastases (2/44) (p = 0.021, G test) (Table 1).
However, no interaction between breast cancer subtype
and site of metastasis was detected (Table 2, p > 0.1, bino-
mial logistic regression model). These results further sup-
port the hypothesis that different isolation techniques
different populations of CTCs may be detected. Correlating
the patient’s follow-up with the results obtained using both
CTC enrichment methods, it could be shown that survival
after brain metastasis diagnosis was significantly associated
with the presence of CTCs (p = 0.033, log-rank test, Fig. 2a).
Using a threshold of ≥ 5 CTCs on the results obtained after
EpCAM-dependent enrichment, a significantly shorter
overall survival time among patients with detectable CTCs
could be seen (p < 0.001, log-rank test, Fig. 2b). In a multi-
variable analysis on the histological subtype and sites of
metastases, the presence of CTCs was significantly
correlated with a hazard ratio of 7.19 (95% CI [1.73,
29.95], p = 0.0067). Similar results were obtained after
EpCAM-independent enrichment, with death confirmed
in 73.3% of CTC-positive and 36.7% of the CTC-negative
patients (p = 0.041, log-rank test, Fig. 2b), but which was
not significant in multivariable analysis.
Detection of copy number alterations in CTCs
To learn more about the chromosomal aberrations
present in BCBM and their changes during the metastasis
process, we analyzed the copy number alteration (CNA)
profiles of CTCs as well as autologous tumor tissue.
CNA profiles were assessed in 28 CTCs from three
different BCBM patients. From all three patients, the
tissue of the corresponding primary breast tumor was
available, as well as brain metastasis tissue from one pa-
tient. In two patients, no brain operation was performed.
The CNA profiles of the single CTCs harbored typical
aberrations corresponding to their primary tumor’s histo-
logical subtype. For instance, gain of chromosome 1p and
loss of 16q are often observed in hormone receptor-posi-
tive tumors [19, 20] and could also be seen in the tumor
cells of the hormone receptor-positive case UKE70
(Fig. 3a). This patient’s tumor cells also carried an amplifi-
cation in each CTC of the 11q13.3 locus containing Cyclin
D1 gene (CCND1), as well as gains of NOTCH3 (19p13.2),
HTERT (5p15.33), and PDPK1 (16p13.3). In general, all
eight CTCs were of high clonality showing very similar
Fig. 1 Number of detected CTCs. Bar chart showing the number of CTCs detected after EpCAM-dependent enrichment (gray) and EpCAM-
independent enrichment (black) per patient along with their histological subtype. TNBC triple-negative breast cancer, HR+ hormone receptor
positive, ERBB+ overexpression of ERBB2
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Table 1 Clinical characteristics. The number of patients tabulated on CTC status and their clinical characteristics. The CTC status was
considered positive if ≥ 5 or ≥ 1 CTCs were detected after EpCAM-dependent or EpCAM-independent enrichment, respectively. p
values were calculated using the G test
≥ 5 CTCs (EpCAM dependent) ≥ 1 CTC (EpCAM independent)
Total (n) Neg (n) Pos (n) p value Total (n) Neg (n) Pos (n) p value
Total 44 35 9 46 31 15
Histology
Ductal 24 20 4 0.655 25 17 8 0.552
Lobular 4 3 1 5 3 2
Others 2 1 1 3 1 2
n.a. 14 13
Age at BM
<Mean 21 15 6 0.213 25 18 7 0.476
>Mean 23 20 3 21 13 8
Hormone
Neg 21 17 4 0.878 20 9 11 0.018
Receptor
Pos 19 15 4 21 17 4
n.a. 4 5
ERBB2
Neg 16 10 6 0.029 15 6 9 0.021
Pos 24 22 2 26 20 6
n.a. 4 5
Subtype
HR-pos 8 5 3 0.102 5 3 2 0.044
TNBC 8 5 3 10 3 7
ERBB2-pos 24 22 2 26 20 6
n.a. 4 5
Brain surgery
No OP 14 10 4 0.388 15 9 6 0.471
OP 30 25 5 20 22 9
n.a. 0 11
Oligo brain met.
Multiple 30 24 6 0.827 28 16 12 0.080
Oligo 13 10 3 17 14 3
n.a. 1 1
Bone met.
No 25 23 2 0.021 25 18 7 0.476
Yes 19 12 7 21 13 8
Liver met.
No 33 28 5 0.165 31 22 9 0.471
Yes 11 7 4 15 9 6
Pulmonary met.
No 36 29 7 0.743 38 28 10 0.064
Yes 8 6 2 8 3 5
BM brain metastasis, OP operation, HR hormone receptor, TNBC triple-negative breast cancer, met. metastasis, n.a. data not available
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CNA profiles and thereby residing all together in unsuper-
vised hierarchical clustering (Fig. 3b).
From case UKE72, a patient diagnosed with triple-
negative breast cancer, 13 single CTCs and the primary
tumor tissue were analyzed. The genomes of the investi-
gated cells and tissue showed a large number of copy
number aberrations, typically found in TNBC patients
[21–23] and also described as a “sawtooth” profile [20].
Table 2 Breast cancer subtype vs metastasis site. Cross table
showing the number of cases of the bone, liver, and pulmonary
metastases found per histological subtype of the primary tumor
Bone met. Liver met. Pulmonary met.
HR-pos 7 2 2
ERBB2-pos 3 3 2
TNBC 14 10 5
HR hormone receptor, TNBC triple-negative breast cancer, met. metastasis
Fig. 2 Survival analyses. Kaplan-Meier estimates for patients without (gray solid lines) and with (black dashed lines) detectable CTCs according to
the combination of enrichment techniques (a), EpCAM-dependent enrichment only (b), and EpCAM-independent enrichment only (c)
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Fig. 3 (See legend on next page.)
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These aberrations included gains of chromosomes impli-
cated in metastatic breast cancer including 3q, 6p21.2
(PIM1), 8q22.1 (CCNE2), 8q4.21 (MYC), 11q13.3
(CCND1), 19p13.2 (NOTCH3), and 20q13.2 (AURKA)
and losses of chromosomes 5q12-13 and 16q. All CTCs
resided together along with the primary tumor when com-
paring the CNA profiles with the other samples (Fig. 3b).
A second case with TNBC, UKE54, all seven of the
analyzed single CTCs showed a high number of small
aberrations, being described as a “firestorm” profile [20].
Although with lower frequency, aberrations typical for
triple-negative and basal-like breast cancer [22, 24] could
be discerned in the CTCs as well as the corresponding
primary tumor and brain metastases (Fig. 3a). Unsuper-
vised hierarchical clustering analyses of all samples dem-
onstrated also a high clonality within case UKE54 as all
CTCs and tumor tissues resided together.
In summary, the CNA patterns showed a high clonality
among different CTCs of the same patient and genomically
resembling the primary breast tumors. In order to find
potential brain metastasis-related aberrations, all samples
were investigated on the most frequent CNAs. Only one re-
gion was gained in all samples located on chromosome
1q22-q23.2 containing among others the well-known gene
MUC1. More interestingly, gain of chromosome 11p11.2
was seen in all but one sample. This genomic region con-
tains the genes AMBRA1, HARBI1, ATG13, ARHGAP1,
ZNF408, F2, CKAP5, MiR5582, SNORD67, LRP4-AS1,
LRP4, and C11orf49.
Mutation analysis in CTCs
In order to discover potential druggable targets, the NGS
exome-seq data were investigated for mutations in known
cancer-associated genes. To prevent the detection of false
positives, mutation analysis was limited to mutations with
a minimal coverage of six reads and reported in the COS-
MIC database only. After filtering, cancer-related muta-
tions could be detected in 12/13 CTCs of case UKE72, 7/7
CTCs of case UKE54, and 7/8 CTCs of case UKE70
(Additional file 1: Data S1). The most frequent mutated
gene was TP53, in which a mutation was detected in 50%
of all CTCs. Other genes that were found to be mutated
in at least 2 CTCs per patient were ARID1A, CDH1, and
TTN. Genes that were mutated in 1 CTC in at least 2
patients were RYR2, LRP2, and PI3KCA. Although more
cancer-related mutations were detected, we considered
them as potentially false positive and therefore not report
them. The most interesting target found was ARID1A,
which is involved in chromatin remodeling and was found
mutated (p.S2264* (stop); c.6791C>G) in CTCs of case
UKE70. Therefore, ARID1A was investigated further in
brain metastasis tissue.
ARID1A expression in brain metastasis tissue
Analyzing our TMA, we classified ARID1A protein
expression as negative, intermediate, or strong. Evaluable
results were obtained from 95 brain metastases. Represen-
tative staining is shown in Additional file 2: Figure S1.
67.4% (64/95) of all brain metastases showed no ARID1A
protein expression, whereas only 8.4% (8/95) of the sam-
ples showed a strong nuclear expression and 24.2% (23/
95) had an intermediate expression. Negative expression
of ARID1A was most commonly seen in TNBC brain
metastases (82.9%, 29/35) compared to 51.3% (19/37) in
ERBB2-positive and 71.4% (10/14) in hormone receptor-
positive metastases (p = 0.017, G test). No other associ-
ation between ARID1A expression in brain metastases
and clinical status was found.
Discussion
Breast cancer brain metastasis (BCBM) has a very poor
prognosis, and reliable blood-based biomarkers are ur-
gently needed to improve treatment options [3]. Detec-
tion of EpCAM-positive CTCs by the FDA cleared
CellSearch System has already been shown to have a
prognostic impact in many tumor entities [25, 26]. Large
meta-analyses on the role of CTCs detected CellSearch Sys-
tem in both early- and late-stage breast cancer patients
have clearly shown their predictive power among breast
cancer patients. Here we used two different methods for
CTC enrichment in BCBM patients’ blood: dependent and
independent of EpCAM, as previous reports have indicated
that brain metastatic patients might have many EpCAM-
negative CTCs [27–29]. Indeed, we could observe that in
our BCBM study population only 20.5% of the patients had
CTCs (≥ 5 CTCs/7.5ml blood) when analyzed by the Cell-
Search System using EpCAM as an enrichment marker,
whereas the EpCAM-independent method detected CTCs
in 32% of patients. Combining both methods for CTC de-
tection, 63.6% of the patients showed CTCs with an overlap
of only 27.3%. Among hormone receptor-positive patients,
very few cases were CTC positive whereas in TNBC
patients the EpCAM-independent enrichment resulted in a
superior detection rate. Therefore, CTC assays based on
epithelial surface markers such as the CellSearch System
might not be detecting CTC populations of a mesenchymal
character, a typical feature of TNBC. In general, the low
CTC counts are a drawback in basic research or clinical
(See figure on previous page.)
Fig. 3 Copy number alterations. a Frequency plots of copy number gain (positive values, green) and loss (negative values, red) along the whole genome
(x-axis) of tumor cells from three BCBM patients. b Unsupervised hierarchical clustering analysis of all individual CNA profiles of CTCs and tumor tissues of
three BCBM patients, along with the corresponding heatmap showing copy number gain (blue) and loss (red) along the whole genome
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tests and may be explained by the fact that the brain consti-
tutes a unique microenvironment, with cells spreading to
the brain having to go through certain steps of transform-
ation in order to penetrate the blood-brain barrier. We have
recently shown that also lung cancer patients with brain
metastases have less CTCs when detected by the EpCAM-
dependent CellSearch system [30]. Interestingly, we could
show both in lung cancer as well as in this study that sur-
vival after brain metastasis diagnosis correlates with CTC
detection when using EpCAM-dependent enrichment. This
indicates that CTCs have a prognostic value in BCBM
patients and regardless of the low counts can still be used
as a prognostic marker for patient outcome.
Single-cell analysis enables characterization of tumor
heterogeneity. For this reason, their characterization is
thought to have a high potential for clinical impact. Here,
we compared the CNA profiles of CTCs and those of
corresponding tumor tissue. We performed CNA profiles
from three patients, all corresponding primary breast tu-
mors and one brain metastasis. We could show that corre-
sponding CTCs resemble those of primary breast tumors,
but identified alterations also in pathways known to be
important in brain metastasis formation including notch
(gain of NOTCH3) and PI3K (gain of PDPK1) pathways
[29, 31, 32]. Interestingly, most of the CTCs within one
patient showed a high clonality indicating that cells compe-
tent for brain metastases have undergone a strict clonal
selection. High clonal restriction is also supported by
the finding by Brastianos et al. in which they showed
that different brain metastases in the same patients
(also subsequential appearance) have remarkable simi-
lar genomes [33].
Mutation analysis showed alterations in cell cycle regu-
lators such as TP53, RB1, and CDKN2A, as well as genes
belonging to the PI3K pathway (PTEN, PIK3CA) and
regulators of EMT (CDH1) and chromatin remodeling
(ARID1A). Inactivating mutations of ARID1A, a subunit of
the SWI/SNF chromatin remodeling complex, have been
commonly reported in multiple human cancers, and espe-
cially in gynecological cancers [34]. Interestingly, ARID1A
mutations frequently co-occur with PIK3CA or PTENmu-
tations in human tumors, and double mutations of Arid1a
with Pten or Pik3ca result in ovarian tumor formation in
mice [35, 36] suggesting a cooperative carcinogenic role of
PI3K and chromatin remodeling pathways. As we and
others have shown the importance of PI3K kinase pathway
in brain metastases [7, 37], we analyzed here the expres-
sion pattern of ARID1A in brain metastases. We could
show that 67% of all brain metastases have no ARID1A
protein expression. The loss of ARID1A seems to be most
commonly seen in TNBC brain metastases (83%) com-
pared to 51% in ERBB2-enriched and 71% in HR-positive
tumors. However, the occurrence of ARID1A mutations
seems to be rare in triple-negative IDC-NST tumors and
more frequently in metaplastic breast carcinoma (1 vs
11%) [38]. ARID1A expression did not correlate with any
other clinicopathological factor, and thus, its role in brain
metastases remains unclear. However, as depletion of
ARID1A protein expression was found to significantly in-
crease the sensitivity of cancer cells towards PI3K and
AKT inhibitors, the expression of ARID1A could serve as
a biomarker to predict the response for the inhibitors [39,
40]. Clearly, further studies need to be performed to valid-
ate these results.
Conclusion
Our study shows the prognostic impact of CTC detection
in BCBM patients. However, low detection rates highlight
the challenges for the detection of CTCs in breast cancer
patients with brain metastasis. Further investigation is re-
quired to identify driver-specific routes to dissemination
to the brain, and implementation of large cohort studies is
needed. Brain metastasis patients still have a very poor
prognosis, and blood-based markers could generate a high
impact on therapeutic management of these patients.
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Additional file 1: Data S1. Genes found to be mutated in CTCs using
NGS exome-seq data. Below each case the frequency of affected genes is
noted as well as for the complete cohort (bottom). (XLSX 9 kb)
Additional file 2: Figure S1. ARID1A staining of breast cancer brain
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